Protecting the World from Pertussis and Other Emerging Diseases

BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure. The company currently distributes a portfolio of vaccines through an established global commercial network and continues to expand its operations across continents.

BioNet Key Facts

Decades of Vaccine Expertise at a Glance

3

3 licensed
recombinant pertussis vaccines

200

200+ qualified and passionate individuals fueling vaccine innovation

25

25+ years’ experience in vaccines

20

20 clinical trials conducts

10

10+ mRNA candidates

BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN

Jakarta, May 28, 2025 — BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on the development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).

Read more

New research boosts future whooping cough vaccines

Researchers at the University of Texas at Austin have discovered two human-derived antibodies, hu1B7 and hu11E6, that effectively neutralize pertussis toxin (PT) by targeting its most vulnerable regions. This breakthrough provides a structural blueprint for improving current acellular pertussis vaccines and developing next-generation formulations like PTgen, a genetically detoxified pertussis toxin. The findings not only support the use of PTgen in enhancing vaccine durability and efficacy but also highlight the potential of these antibodies as therapeutic tools, particularly for protecting infants who are most at risk from severe pertussis infection.

Read more

New Discoveries

Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses

Read more

Infant responses to primary immunization following vaccination in pregnancy with varying doses of recombinant acellular pertussis vaccine alone or combined with tetanus-diphtheria

Read more